Surface modification of nanoparticles is a well-established methodology to alter their properties to enhance circulation half-life. While literature studies using conventional, in vitro characterization are routinely used to evaluate the biocompatibility of such modifications, relatively little attention has been paid to assess the stability of such surface modifications in physiologically relevant conditions. Here, microfluidic devices were used to study the effect of factors that adversely impact 
| I N TR ODU C TI ON
Numerous nanoparticles have been developed over the years for therapeutic applications where they hold great promise for effective therapeutic drug delivery, primarily in oncology.
1,2 These nanoparticles include polymeric systems, liposomes, micelles and nanocrystals, among others. [3] [4] [5] [6] Regardless of the composition of nanoparticles, their surface is often modified to extend their blood circulation using polyethyleneglycol (PEG) for instance, or with targeting ligands to enhance tissuetargeting. [7] [8] [9] [10] A large number of studies have demonstrated the ability of PEG to minimize opsonization and clearance by the reticuloendothelial system sequestration. 9, 11, 12 At the same time, several targeting ligands including small molecules, peptides, and antibodies have been successfully used for targeting purposes. [11] [12] [13] [14] A number of studies have focused on the design and characterization of surface coating of nanoparticles. 15, 16 For example, studies have focused on characterization and optimization of PEG coating and surface ligand density. [17] [18] [19] These surface coatings are often developed based on in vitro studies and relatively little is known about their stability in vivo. In addition, close contact of these nanoparticles with endothelial cells in vivo may also adversely impact their stability. In this study, we systematically assess the role of vascular flow and endothelial cells in the stability of surface coating on nanoparticles using endothelial cell-laden microfluidic devices.
The nanoparticles used in this study were rod-shaped camptothecin (CPT) nanocrystals, 20, 21 modified with PEG which was physically or chemically tethered to the surface. Previous studies in our and other laboratories have demonstrated the utility of nanocrystals for therapeutic applications. [22] [23] [24] [25] [26] [27] An additional variant of CPT nanocrystal, carrying PEG-folic acid (FA) conjugate was also investigated. These nanocrystalline camptothecin-based nanoparticles were selected as a test particle group primarily based on the previous research performed on these particles in our laboratory. Similar studies could be performed using other nanoparticle types. Two types of microfluidic devices were used; microvascular network devices (MNs) that mimic complex vasculature and fluid flow conditions observed in vivo or linear channel device's (LCs) which offer a simple and constant flow system.
| M E TH ODS

| Preparation and analysis of camptothecin nanocrystals
All CPT nanocrystals were prepared using the solvent diffusion method as described previously 20 as shown in Figure 1 .
| CPT 1 PEG nanoparticles (PEG physically adsorbed on CPT)
About 5 ml of 0.8 mg/ml of CPT (Sigma Aldrich) and 3.2 mg/ml DSPE PEG2K Amine (Avanti Polar Lipids) in DMSO solution were pipetted dropwise into a 120 ml water mixture containing 1% w/w alpha-tocopherol (Sigma). The mixture was stirred at 800 rpm under constant ultrasonication at room temperature (228C) for 1 hr. CPT 1 PEG nanocrystals formed at the boundary where DMSO diffused into the water. The CPT 1 PEG nanocrystals were then centrifuged three times at 208C with milliQ water (18.2 MXcm) at 3,500 rpm. Schematic representation of three CPT nanoparticle scaffolds prepared and used in this study. In case of CPT 1 PEG, the lipid chain of DSPE-PEG is expected to noncovalently associate with the hydrophobic surface of CPT as shown in the schematic. In case of CPT-PEG, two configurations are likely; the amine group in DSPE-PEG-amine is chemically conjugated to the surface of CPT, thus exposing the lipid chain outside. DSPE-PEG-amine may also fold due to hydrophobic interactions between the lipid chain and hydrophobic CPT surface leading to anchoring of the lipid chain on the CPT surface thus exposing PEG in a loop. For CPT 1 PEG-FA, the DSPE-PEG-FA is expected to anchor on CPT by its hydrophobic tail, thus exposing FA outwards (228C) for 1 hr. After 1 hr, the CPT 1 PEG-FA nanocrystals were then centrifuged three times at 208C with milliQ water (18.2 MXcm) at 3,500 rpm. Presence of folic acid was quantified using absorbance at 290 and 370 nm, and CPT was quantified using fluorescence at 366/ 434 nm-both utilized a spectrophotometer (Tecan M220 Infinite Pro).
DSPE PEG2K Amine was quantified using ICP-MS as used for CPT 1 PEG constructs.
| CPT-PEG nanoparticles (PEG chemically conjugated to CPT)
To prepare CPT-PEG, unmodified Camptothecin nanocrystal surfaces were activated with carbonyldiimidazole (CDI, MR 1:10, Sigma) in pH 7.4 1x PBS buffer for 5 min. The activated particles were then centrifuged at 5,000 rpm, for 30 min at 208C and washed three times using DI water. They were then mixed with DSPE PEG2K Amine (PEG-NH 2 , MR 1:3) in 1x PBS pH 7.4 and left for overnight coupling at 48C. Finally, the unreacted PEG-amine was removed after three washes with DI water.
In some experiments, FA was directly conjugated to CPT (CPT-FA).
To prepare these particles, 600 ml of 0.5 mg/ml of unmodified CPT nanocrystals were added to 400 ml of the CDI stock solution. This solution was allowed to rotate for 15 min at room temperature. CDIactivated CPT nanocrystals were spun down at 5,000 rpm for 15 min at room temperature. Pellets were collected, washed with DI water, and resuspended in a 0.8 mg/ml solution of Folic Acid in MQH 2 O at pH 5. Folic acid and CDI activated CPT nanocrystals were incubated together and rotated overnight at 48C. CPT-FA were then spun down at 5,000 rpm, 30 min at 208C and washed two times at these conditions in MQH 2 O. CPT and FA presence were determined via absorbance at 366 and 290 nm respectively using independent CPT and FA standard curves on the Tecan M200 PlateReader.
Morphologies of CPT 1 PEG, CPT-PEG, and CPT 1 PEG-FA nanocrystals were analyzed using a scanning electron microscope (SEM).
Surface charges of all nanocrystalline scaffolds suspended in 1x PBS pH 7.4 were measured as zeta potential (ZP) using a NanoseriesZetasizer (Malvern). lacking endothelial cells, the devices were subjected to the same preparative conditions as described above.
| Cell culture
| Endothelial cell viability within MNs and LCs
Cell viability prior to the infusion of nanocrystals within the MNs was analyzed using SYTOX Green Nucleic Acid Stain and LYSOTracker Red DND (Invitrogen). EA.hy926 cells were seeded and cultured in MNs at a density of 100,000 cells/ml in DMEM, 10% FBS, 1% Pen-Strep. Cells were allowed to attach overnight and grown for n 5 3 days before administering cell viability dyes at 4 ml/min for 30 min. Fluorescent images were taken using FITC and TRITC filters on an Olympus CKX-41 followed by processing and quantitation using ImageJ.
MNs and LCs were also imaged using phase contrast on brightfield settings on day 5 post seeding and after unmodified CPT nanocrystals infusion at 4 ml/min for 500 ml. Post infusion device channels were washed with DMEM, 10% FBS, 1% Pen-Strep at 2 ml/min for 50 ml. 
| R E SU LTS
All CPT nanocrystals were flown through MNs and LCs at 4 ll/min.
These flow rates were selected to maintain similar flow conditions and shear stresses within the devices that were sufficiently low so as to not cause endothelial cell detachment while also maintaining the lower range limit of physiologically relevant shear stresses associated with diseased vasculature. 20, 30, 31 Due to complex bifurcations, loops, and intersections, the shear stresses at the core of the MNs are expected to drop with a return to inlet level shear stresses upon the reunification of the bifurcated channels into the linear portion leading to the exit port. 32 
| D I SCUSSION
This study used a combination of microfluidic devices to probe the effects of flow and endothelial cell contact on ligand shedding from nanoparticles. Camptothecin nanocrystals were used as a test particle system for use within the microfluidic devices. Several studies report the use of microfluidic devices for studying tumor microenvironments, target-screening, and cancer metastases modeling. [33] [34] [35] [36] [37] [38] [39] [40] This study aims to use microfluidic devices to specifically probe the combined effects of complex architecture and flow-induced shear/wall contact by nanocrystals and other drug delivery carriers during flow in the vascular network. PEG was attached to camptothecin nanocrystals either via chemical conjugation (CPT-PEG) or physical adsorption (CPT 1 PEG).
The third scaffold involved the conjugation of a PEG to folic acid (PEG-FA), which has been previously shown to target breast cancer cells. 41 The PEG-FA conjugates were physically adsorbed to the surface of a camptothecin nanocrystal (CPT 1 PEG-FA).
Two types of microfluidic devices were used in this study, LCs sented here to other nanoparticles should be done with caution, the findings clearly demonstrate the necessity of assessing these issues during translation of nanoparticles from in vitro to in vivo studies.
